Elcatonin
Also known as: Carbocalcitonin, Eel calcitonin, Eel calcitonin analogue, ELC, Elcitonin, SM-201
Source Elcatonin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Elcatonin is a synthetic eel‑derived calcitonin analogue approved for prescription use in osteoporosis and related bone pain. It is administered by intramuscular or subcutaneous injection and has been studied for chronic back/knee pain, acute vertebral fracture pain, and its ability to increase lumbar bone mineral density over several years.
Mechanism of Action
Elcatonin mimics endogenous calcitonin, binding to calcitonin receptors on osteoclasts to suppress bone resorption and lower serum calcium. The peptide also exerts central analgesic effects, likely via modulation of spinal pain pathways and release of endogenous opioids, contributing to its reported pain‑relieving properties.
What the Research Shows
Randomised trials have compared elcatonin with risedronate, NSAIDs, and placebo. A 2011 study found greater reduction of chronic back and knee pain versus risedronate, while a 2016 trial showed superior relief of acute lumbar pain after vertebral fracture compared with NSAIDs. A 3‑year placebo‑controlled trial (2019) demonstrated a significant increase in lumbar BMD but no reduction in vertebral fracture incidence, with a higher rate of adverse drug reactions. A 2019 network meta‑analysis of 16 trials reported comparable fracture rates and BMD changes to other osteoporosis drugs, but notable pain‑relief benefits and higher complication rates. A 2004 systematic review of hypercalcaemia treatments indicated incadronate was more effective than elcatonin, suggesting limited utility in that indication.
Reported Benefits
Evidence supports elcatonin’s analgesic effect in chronic musculoskeletal pain and acute vertebral fracture pain, with measurable reductions in pain scores versus risedronate or NSAIDs. Weekly administration over three years modestly increases lumbar BMD, indicating some bone‑protective activity. In combination regimens, it may provide comparable fracture outcomes to other osteoporosis agents while offering additional pain relief.
Limitations of the Evidence
Large, long‑term trials have not demonstrated a statistically significant reduction in vertebral or non‑vertebral fractures. Safety data show a higher incidence of adverse drug reactions compared with placebo. Comparative effectiveness for hypercalcaemia is inferior to incadronate. Existing studies vary in design, dosage, and patient populations, leaving uncertainty about optimal dosing and long‑term benefit‑risk balance.
Safety Considerations
Clinical trials report a greater frequency of adverse drug reactions in elcatonin recipients, though no new safety signals emerged over three years. Reported events are consistent with calcitonin class effects (e.g., nausea, flushing, hypersensitivity). Caution is advised in patients with a history of allergic reactions to peptide hormones, and monitoring for adverse effects is recommended during therapy.
How It Is Administered
Elcatonin is delivered by injection, either intramuscularly or subcutaneously. Study protocols have used 20 units administered once weekly or a single 20‑unit intramuscular dose for pain studies. Formulations are supplied as sterile injectable solutions suitable for these routes.
Routes of Administration
Goals & Uses
- Osteoporosis treatmentBone MetabolismModerate
- Hypercalcemia managementMineral MetabolismModerate
- Paget's disease of boneBone MetabolismModerate
- Prevention of bone loss in immobilizationBone MetabolismLow
- Analgesic effect in bone painPain ManagementModerate
Contraindications
- Hypersensitivity to elcatonin or calcitonin analoguesAllergyHigh
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Hypersensitivity to calcitoninAllergyHigh
- HypocalcemiaElectrolyte DisorderHigh
Adverse Effects
- Facial flushingCardiovascular/DermatologicCommon
- Allergic reactionsImmunologicalRare
- Injection site reactionsLocalCommon
- FlushingVascularCommonWarmth and redness of the skin
- Nausea and vomitingGastrointestinalCommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- HypocalcemiaMetabolicUncommon
- DizzinessNeurologicUncommonFeeling faint, lightheaded, or unsteady
Drug Interactions
- Loop diureticsModerate
- BisphosphonatesLow
- Calcium supplementsModerate
Population Constraints
- Renal impairmentOrgan ImpairmentRelative
- Severe renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Lactating womenReproductiveRelative
- Elderly patientsAgeRelative
- ChildrenPediatricAbsolute
Regulatory Status
- European UnionUnapprovedNo EMA approval.
- JPApprovedApproved: osteoporosis, hypercalcemiaMarketed as Elcatonin injection.
- United StatesUnapprovedNot evaluated by FDA.
- United KingdomUnapprovedNot approved in the UK; available primarily in Japan and some Asian markets
Approved in Japan (JP) for osteoporosis; not approved by FDA (US) or EMA (EU).
Evidence & Sources
- Journal ArticleModerateFujita T, et al.2011-01-01T00:00:00.000000Z
- Journal ArticleHighSaunders Y, et al.2004-01-01T00:00:00.000000Z
- Journal ArticleModerateSugimoto T, et al.2019-01-01T00:00:00.000000Z
- Journal ArticleHighChen JF, et al.2015-01-01T00:00:00.000000Z
- Journal ArticleHighChen WC, Lin EY, Kang YN2019-01-01T00:00:00.000000Z
- Journal ArticleModerateEndo N, et al.2017-01-01T00:00:00.000000Z
Frequently Asked Questions
What conditions is elcatonin used to treat?
Elcatonin is prescribed for osteoporosis and associated bone pain, and it has been investigated for acute pain after vertebral fractures. It is not approved for hypercalcaemia of malignancy, where other agents are preferred.
Does elcatonin prevent fractures?
Current evidence shows that weekly elcatonin increases lumbar bone density but does not significantly lower the incidence of new vertebral or non‑vertebral fractures in large, long‑term trials.
How quickly does elcatonin relieve pain?
Clinical studies report measurable pain reduction within weeks; a 6‑week trial showed greater improvement in pain scores compared with NSAIDs, and chronic pain scores improved over several months in a separate study.
Are there any common side effects?
Patients may experience typical calcitonin‑related reactions such as nausea, flushing, or mild hypersensitivity. A higher overall rate of adverse drug reactions was observed versus placebo, though serious events were rare.
How is the drug administered?
Elcatonin is given by injection—either intramuscularly or subcutaneously. Research dosing has used 20 units once weekly or a single 20‑unit intramuscular injection for pain relief.
What is Elcatonin?
Elcatonin is a synthetic eel‑derived calcitonin analogue approved for prescription use in osteoporosis and related bone pain. It is administered by intramuscular or subcutaneous injection and has been studied for chronic back/knee pain, acute vertebral fracture pain, and its ability to increase lumbar bone mineral density over several years.
What is Elcatonin used for?
Elcatonin is educationally associated with: Osteoporosis treatment, Hypercalcemia management, Paget's disease of bone, Prevention of bone loss in immobilization, Analgesic effect in bone pain. Educational only — not medical advice.
How is Elcatonin administered?
Recorded routes of administration: Intramuscular, Subcutaneous.
What are the potential side effects of Elcatonin?
Reported adverse effects include: Facial flushing, Allergic reactions, Injection site reactions, Flushing, Nausea and vomiting, Nausea, Hypocalcemia, Dizziness. This list is not exhaustive — consult a qualified clinician.
Who should avoid Elcatonin?
Recorded contraindications: Hypersensitivity to elcatonin or calcitonin analogues, Pregnancy, Hypersensitivity to calcitonin, Hypocalcemia. Consult a qualified clinician before use.